Valuation: AbbVie Inc.

Capitalization 35TCr 30TCr 28TCr 26TCr 48TCr 33,26200Cr 50TCr 3,26000Cr 1,28400Cr 15,93200Cr 1,33000Cr 1,30300Cr 56,52700Cr P/E ratio 2026 *
23x
P/E ratio 2027 * 18x
Enterprise value 41TCr 35TCr 32TCr 30TCr 56TCr 38,16700Cr 57TCr 3,74000Cr 1,47300Cr 18,28200Cr 1,52600Cr 1,49500Cr 64,86300Cr EV / Sales 2026 *
6.07x
EV / Sales 2027 * 5.45x
Free-Float
96.39%
Yield 2026 *
3.44%
Yield 2027 * 3.59%
1 day-2.25%
1 week-3.80%
Current month-7.81%
1 month-2.23%
3 months-8.07%
6 months-12.32%
Current year-12.25%
1 week 199.81
Extreme 199.81
212.35
1 month 199.81
Extreme 199.81
220.45
Current year 199.81
Extreme 199.81
237.11
1 year 176.11
Extreme 176.11
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO 59 23/06/2022
Compliance Officer - 01/01/2024
Director TitleAgeSince
Director/Board Member 65 01/01/2013
Director/Board Member 74 01/01/2013
Director/Board Member 68 01/01/2013
Change 5d. change 1-year change 3-years change Capi.($)
-2.25%-3.80%+15.38%+23.45% 36TCr
+2.04%+1.82%+11.35%+139.20% 81TCr
-0.03%-5.27%+43.33%+38.98% 54TCr
+2.07%+0.95%+25.59%+13.86% 32TCr
-0.16%-1.56%+43.35%+19.28% 31TCr
-0.45%-2.33%+27.46%+30.00% 28TCr
+0.29%-4.25%+42.95%-2.15% 28TCr
+0.31%-0.66%+24.25%+41.85% 19TCr
+0.77%-1.13%-36.15%-57.22% 17TCr
-0.29%-4.92%+25.96%+53.52% 17TCr
Average +0.33%-2.33%+22.35%+30.08% 34.31TCr
Weighted average by Cap. +0.60%-1.99%+23.96%+48.76%

Financials

2026 *2027 *
Net sales 6.71TCr 5.72TCr 5.25TCr 4.96TCr 9.16TCr 6,29000Cr 9.36TCr 62TCr 24TCr 3,01300Cr 25TCr 25TCr 10,68900Cr 7.25TCr 6.19TCr 5.67TCr 5.37TCr 9.9TCr 6,80000Cr 10TCr 67TCr 26TCr 3,25700Cr 27TCr 27TCr 11,55500Cr
Net income 1.59TCr 1.35TCr 1.24TCr 1.18TCr 2.17TCr 1,48900Cr 2.22TCr 15TCr 5.75TCr 71TCr 5.95TCr 5.83TCr 2,53000Cr 1.96TCr 1.68TCr 1.54TCr 1.45TCr 2.68TCr 1,84100Cr 2.74TCr 18TCr 7.11TCr 88TCr 7.36TCr 7.21TCr 3,12900Cr
Net Debt 5.23TCr 4.46TCr 4.09TCr 3.87TCr 7.14TCr 4,90500Cr 7.3TCr 48TCr 19TCr 2,35000Cr 20TCr 19TCr 8,33600Cr 4.06TCr 3.47TCr 3.18TCr 3.01TCr 5.55TCr 3,81000Cr 5.67TCr 37TCr 15TCr 1,82500Cr 15TCr 15TCr 6,47500Cr
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
22/26/22 200.50 $ -2.25% 76,45,617
21/26/21 205.12 $ +0.69% 77,72,128
20/26/20 203.71 $ -2.24% 57,74,268
17/26/17 208.38 $ -0.29% 89,86,577
16/26/16 208.99 $ +0.27% 50,75,394
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
200.50USD
Average target price
249.43USD
Spread / Average Target
+24.41%

Quarterly revenue - Rate of surprise